-
1 Comment
Suven Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 4.2% above its 200 day moving average.
From a valuation standpoint, the stock is 179.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13.4.
Based on the above factors, Suven Pharmaceuticals Limited gets an overall score of 1/5.
| Exchange | NSE |
|---|---|
| CurrencyCode | INR |
| ISIN | INE03QK01018 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Target Price | 1396.6666 |
|---|---|
| Beta | 1.13 |
| Market Cap | 275B |
| PE Ratio | 98.97 |
| Dividend Yield | None |
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research services. It also manufactures finished dosage formulations for pharmaceutical companies; and specialty chemicals, such as electronic chemicals. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is based in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SUVENPHAR.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
